Inventor · disambiguated record
Matthew L. Sherman
Also filed as: SHERMAN MATTHEW · SHERMAN MATTHEW L
13 granted patents·33 pending applications·469 citations·filing 1999–2023
94Inventor score
Files withACCELERON PHARMA INC31SHERMAN MATTHEW L4WYETH CORP3DECIPHERA PHARMACEUTICALS LLC2INST GENETICS LLC2
Top patents by PatentIndex Score
46 records- 0198US7988973B2Activin-ActRII antagonists and uses for increasing red blood cell levelsACCELERON PHARMA INC·Filed 2007·Granted Aug 2, 2011·108 cites·37 claims
- 0297US9353356B2Activin-actriia antagonists for treating a follicle-stimulating horomone-secreting pituitary tumorACCELERON PHARMA INC·Filed 2013·Granted May 31, 2016·36 cites·45 claims
- 0397US8367611B2Activin-actriia antagonists for inhibiting germ cell maturationACCELERON PHARMA INC·Filed 2011·Granted Feb 5, 2013·35 cites·19 claims
- 0497US8007809B2Activin-actrii antagonists and uses for increasing red blood cell levelsACCELERON PHARMA INC·Filed 2008·Granted Aug 30, 2011·83 cites·37 claims
- 0597US7960343B2Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretionACCELERON PHARMA INC·Filed 2008·Granted Jun 14, 2011·48 cites·40 claims
- 0696US10550170B2Methods for treating vascular eye disorders with actrii antagonistsACCELERON PHARMA INC·Filed 2016·Granted Feb 4, 2020·21 cites·44 claims
- 0794US9919030B2Follistatin fusion proteins and uses thereofACCELERON PHARMA INC·Filed 2015·Granted Mar 20, 2018·5 cites·23 claims
- 0894US8895016B2Antagonists of activin-actriia and uses for increasing red blood cell levelsSHERMAN MATTHEW L·Filed 2009·Granted Nov 25, 2014·77 cites·23 claims
- 0992US10093707B2Antagonists of activin-ActRIIa and uses for increasing red blood cell levelsACCELERON PHARMA INC·Filed 2014·Granted Oct 9, 2018·16 cites·6 claims
- 1087US11524990B2Methods for treating vascular eye disorders with ActRII antagonistsACCELERON PHARMA INC·Filed 2019·Granted Dec 13, 2022·2 cites·43 claims
- 1185US7727968B2Combination therapy for the treatment of acute leukemia and myelodysplastic syndromeWYETH LLC·Filed 2007·Granted Jun 1, 2010·5 cites·20 claims
- 1277US6509321B1Treatment of Kaposi's sarcoma with IL-12INST GENETICS LLC·Filed 2000·Granted Jan 21, 2003·9 cites·12 claims
- 1376US2022204588A1Activin-actrii antagonists and uses for increasing red blood cell levelsACCELERON PHARMA INC·Filed 2021·Application pending·0 cites
- 1475US2010008918A1Methods for dosing an actriib antagonist and monitoring of treated patientsACCELERON PHARMA INC·Filed 2009·Application pending·0 cites
- 1574US2021355191A1Activin-actrii antagonists and uses for increasing red blood cell levelsACCELERON PHARMA INC·Filed 2020·Application pending·0 cites
- 1674US2022118049A1Methods for dosing an actriib antagonist and monitoring of treated patientsACCELERON PHARMA INC·Filed 2021·Application pending·0 cites
- 1774US2022204576A1Antagonists of activin-actriia and uses for increasing red blood cell levelsACCELERON PHARMA INC·Filed 2021·Application pending·0 cites
- 1874US2010028332A1Antagonists of actriib and uses for increasing red blood cell levelsACCELERON PHARMA INC·Filed 2009·Application pending·0 cites
- 1971US2021355181A1Antagonists of activin-actriia and uses for increasing red blood cell levelsACCELERON PHARMA INC·Filed 2020·Application pending·0 cites
- 2070US2020360475A1Methods for dosing an actriib antagonist and monitoring of treated patientsACCELERON PHARMA INC·Filed 2020·Application pending·0 cites
- 2170US2021038689A1Methods for dosing an activin-actriia antagonist and monitoring of treated patientsACCELERON PHARMA INC·Filed 2020·Application pending·0 cites
- 2269US2021269494A1Methods for treating fatty liver diseaseACCELERON PHARMA INC·Filed 2020·Application pending·0 cites
- 2368US6423308B1Treatment of Kaposi's sarcoma with IL-12INST GENETICS LLC·Filed 1999·Granted Jul 23, 2002·24 cites·12 claims
- 2466US2020031903A1Activin-actrii antagonists and uses for increasing red blood cell levelsACCELERON PHARMA INC·Filed 2019·Application pending·0 cites
- 2563US2024245660A1Methods of treating gastrointestinal stromal tumorsDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Application pending·0 cites
- 2662US2016279203A1Methods for dosing an activin-actriia antagonist and monitoring of treated patientsACCELERON PHARMA INC·Filed 2016·Application pending·0 cites
- 2762US2016279197A1Methods for dosing an actriib antagonist and monitoring of treated patientsACCELERON PHARMA INC·Filed 2016·Application pending·0 cites
- 2862US2020255495A1Antagonists of actriib and uses for increasing red blood cell levelsACCELERON PHARMA INC·Filed 2019·Application pending·0 cites
- 2961US2019225664A1Antagonists of activin-actriia and uses for increasing red blood cell levelsACCELERON PHARMA INC·Filed 2018·Application pending·0 cites
- 3060US2024180923A1Methods of treating disorders with ulk inhibitorsDECIPHERA PHARMACEUTICALS LLC·Filed 2023·Application pending·0 cites
- 3160US2010015144A1Methods for dosing an activin-actriia antagonist and monitoring of treated patientsACCELERON PHARMA INC·Filed 2009·Application pending·0 cites
- 3259US2012003218A1Antagonists of actriib and uses for increasing red blood cell levelsSHERMAN MATTHEW L·Filed 2011·Application pending·0 cites
- 3358US2019062392A1Methods for treating fatty liver diseaseACCELERON PHARMA INC·Filed 2018·Application pending·0 cites
- 3456US2018009872A1Antagonists of actriib and uses for increasing red blood cell levelsACCELERON PHARMA INC·Filed 2017·Application pending·0 cites
- 3555US2012052067A1Activin-actrii antagonists and uses for increasing red blood cell levelsSHERMAN MATTHEW L·Filed 2011·Application pending·0 cites
- 3655US2016319254A1Activin-actriia antagonists for inhibiting germ cell maturationACCELERON PHARMA INC·Filed 2016·Application pending·0 cites
- 3753US2016318983A1Methods for treating fatty liver diseaseACCELERON PHARMA INC·Filed 2016·Application pending·0 cites
- 3852US2011129469A1Methods for treating fatty liver diseaseACCELERON PHARMA INC·Filed 2010·Application pending·0 cites
- 3950US2006142393A1Bis(thio-hydrazide amides) for treatment of hyperplasiaSHERMAN MATTHEW L·Filed 2005·Application pending·0 cites
- 4048US2014193425A1Treatment of cancer with alk1 antagonistsACCELERON PHARMA INC·Filed 2013·Application pending·0 cites
- 4145US2003190305A1Treatment of Kaposi's sarcoma with IL-12WYETH AND NAT INST OF HEALTH·Filed 2002·Application pending·0 cites
- 4243US2004258662A1Antineoplastic agentsWYETH CORP·Filed 2004·Application pending·0 cites
- 4342US2004176339A1Antineoplastic combinationsWYETH CORP·Filed 2004·Application pending·0 cites
- 4439US2005272717A1Treatment of aromatase inhibitor therapy-related osteoporosisJENKINS SIMON N·Filed 2005·Application pending·0 cites
- 4533US2005272758A1Antineoplastic combinations of CCI-779 and rituximabWYETH CORP·Filed 2005·Application pending·0 cites
- 4633US2013202594A1ALK1 Antagonists and Their Uses in Treating Renal Cell CarcinomaBHATT RUPAL S·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Matthew L. Sherman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →